Evidence map›Paper›PMID 34703180›Full record

Trial reportEthiopian journal of health sciences2021

The Effect of Oral Simvastatin on the Clinical Outcome of Patients with Severe Traumatic Brain Injury: A Randomized Clinical Trial.

Sajad Shafiee, Alireza Zali, Misagh Shafizad, Amir Emami Zeydi, Saeid Ehteshami, Fatemeh Rezaii, Abbas Tafakhori, Abolhasan Ertiaei, Hadi Darvishi-Khezri, Mohammad Khademloo and 1 more

Open access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Ethiopian journal of health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. HMG-CoA Reductase Inhibitors for Traumatic Brain Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Sajad ShafieeDepartment of Neurosurgery, Orthopedics Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Alireza ZaliFunctional Neurosurgery Research Center, Shohadaye Tajrish Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Misagh ShafizadDepartment of Neurosurgery, Orthopedics Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Amir Emami ZeydiDepartment of Medical-Surgical Nursing, Nasibeh School of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, Iran.
Saeid EhteshamiDepartment of Neurosurgery, Orthopedics Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Fatemeh RezaiiStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Abbas TafakhoriIranian Center of Neurological Research (ICNR), Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abolhasan ErtiaeiDepartment of Neurosurgery, Imam Khomeini Hospital, Tehran University of Medical Science, Tehran, Iran.
Hadi Darvishi-KhezriThalassemia Research Center (TRC), Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mohammad KhademlooDepartment of Community Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Reza Jalili KhoshnoodFunctional Neurosurgery Research Center, Shohadaye Tajrish Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mazandaran University of Medical Sciences · IRImam Khomeini Hospital · IRIranshahr University · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite recent promising pharmacological and technological advances in neurosurgical intensive care, the overall TBI-related mortality and morbidity remain high and still pose a major clinical problem. The aim of this study was to evaluate the effect of oral simvastatin on the clinical outcome of patients with severe TBI. Methods: In a double-blind placebo-controlled randomized clinical trial a total of 98 patients with severe TBI in Imam Khomeini Hospital in Sari, Iran, were evaluated. Patients who meet the inclusion criteria were randomly allocated into two groups (n=49). In addition to supportive therapies, the intervention group received oral simvastatin (40 mg, daily) for 10 days, and the control group received the placebo (10 days). Patients' Glasgow coma scale (GCS) score, in hospital mortality, duration of mechanical ventilation and length of ICU and neurosurgery ward stay were evaluated during three-time intervals (T1: admission, T2: discharge and T3: one month after discharge). Results: The percentage of conscious patients was 18.9% (7 cases) in the simvastatin group and 3.1% (1 case) in controls (P=0.06) at T2. One month after discharge (T3) the proportion of conscious patients significantly increased in the simvastatin group compared to control group (64.9 % versus 28.1 %; P=0.002). There was no significant difference for the mean of GCS score between the simvastatin group and control group at T1 (6.41 ± 1.30 versus 6.41 ± 1.28, respectively; P = 0.98). However, the mean score of GCS in patients who received simvastatin was significantly greater than controls at T2 and T3 (p<0.05). There was no significant differences between two group in-terms of length of mechanical ventilation, ICU and neurosurgery ward stay. Conclusion: According to the results of this study it seems that using simvastatin may be an effective and promising therapeutic modality for improving GCS score during TBI recovery.

Indexed as

Brain Injuries, TraumaticSimvastatinGlasgow Coma ScaleHospital MortalityHumansTreatment OutcomeSimvastatinBrain InjuriesGlasgow Outcome ScalePatient Outcome AssessmentSimvastatinTraumatic

Identifiers

PMID34703180
PMCPMC8512953
OpenAlexW3210212678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.